ResearcherUniversity of Liverpool Molecular and Clinical Cancer Medicine /UCD Duncan Building / Daulby Street / LiverpoolNo recent work listed

Daniel Palmer

Provisional: name at one institution (moderate confidence)As of 10 November 2026

Known by name at one institution; no external author ID yet. Name as it appears in ClinicalTrials.gov.

Their work

Papers: 0
Trials: 1 (principal investigator on 1)
Grants: 0
Collaborators: 4

Papers, trials and grants by year

2012: 1 trial

Trials 1

Antigen-specific Cancer Immunotherapy (TG01) and Gemcitabine as Adjuvant Therapy in Resected Pancreatic Cancer Principal investigator NCT02261714 ↗

Closest collaborators

The 4 strongest of 4 ranked by shared papers, trials and grants, with recent and small-team work weighing most.

Juan W. Valle · 1 shared trial, 2012
- Trial Antigen-specific Cancer Immunotherapy (TG01) and Gemcitabine as Adjuvant Therapy in Resected Pancreatic Cancer NCT02261714 ↗
Svein Dueland · 1 shared trial, 2012
- Trial Antigen-specific Cancer Immunotherapy (TG01) and Gemcitabine as Adjuvant Therapy in Resected Pancreatic Cancer NCT02261714 ↗
Yuk Ting MA · 1 shared trial, 2012
- Trial Antigen-specific Cancer Immunotherapy (TG01) and Gemcitabine as Adjuvant Therapy in Resected Pancreatic Cancer NCT02261714 ↗
Emiliano Calvo · 1 shared trial, 2012
- Trial Antigen-specific Cancer Immunotherapy (TG01) and Gemcitabine as Adjuvant Therapy in Resected Pancreatic Cancer NCT02261714 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (the fewest links first, then the links with the most shared work). Built from public records only; no contact details are kept.